Lohse Ines, Wildermuth Erin, Brothers Shaun P
Department of Psychiatry and Behavioral Sciences, Center for Therapeutic Innovation University of Miami Miller School of Medicine, University of Miami, Miami, FL, USA.
Molecular Therapeutics Shared Resource, Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, FL, USA.
Oncotarget. 2018 Oct 23;9(83):35448-35457. doi: 10.18632/oncotarget.26234.
Naturally occurring small molecule compounds have long been in the spotlight of pancreatic cancer research as potential therapeutics to prevent cancer progression and sensitize chemoresistant tumors. The hope is that terminal pancreatic cancer patients receiving aggressive chemotherapy can benefit from an increase in treatment efficacy without adding further toxicity by way of utilizing natural compounds. While preclinical studies on a number of natural compounds, such as resveratrol, curcumin, rapalogs and cannabinoids, show promising preclinical results, little has translated into clinical practice, though a number of other compounds hold clinical potential. Nevertheless, recent advances in compound formulation may increase the clinical utility of these compounds.
天然存在的小分子化合物长期以来一直是胰腺癌研究的焦点,有望成为预防癌症进展和使化疗耐药肿瘤敏感化的潜在疗法。人们希望,接受积极化疗的晚期胰腺癌患者能够通过使用天然化合物提高治疗效果,同时不增加额外毒性。虽然对一些天然化合物(如白藜芦醇、姜黄素、雷帕霉素类似物和大麻素)的临床前研究显示出了有前景的临床前结果,但很少能转化为临床实践,不过其他一些化合物具有临床潜力。尽管如此,化合物制剂方面的最新进展可能会提高这些化合物的临床应用价值。